Cartesian Therapeutics, Inc.

DB:1S70 Stock Report

Market Cap: €495.2m

Cartesian Therapeutics Past Earnings Performance

Past criteria checks 0/6

Cartesian Therapeutics's earnings have been declining at an average annual rate of -74.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 33.1% per year.

Key information

-74.1%

Earnings growth rate

-50.8%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate-33.1%
Return on equity-32,557.0%
Net Margin-589.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Cartesian Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:1S70 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2448-282390
30 Jun 2454-267390
31 Mar 2426-288380
31 Dec 2326-257350
30 Sep 23127-1410
31 Dec 2211135240
31 Dec 2185-26210

Quality Earnings: 1S70 is currently unprofitable.

Growing Profit Margin: 1S70 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 1S70's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 1S70's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1S70 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-21.2%).


Return on Equity

High ROE: 1S70 has a negative Return on Equity (-32557.05%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies